Inventurus Knowledge Solutions: Key stock metrics 2026

Stock price snapshot (June 2026)

Inventurus Knowledge Solutions Limited (IKS, ticker: INVU) was quoted at ₹1,687.20 on 23-Jun-2026 at 14:55:45 IST (all price values in ₹). Another reported snapshot shows the share price at ₹1,699.60, down ₹4.70 (-0.28%) on the day. The same dataset notes that, as of 29-06-2026, the share price was ₹1,699.60 versus a previous close of ₹1,704.30.

These data points place IKS among actively traded mid-cap healthcare technology names that investors track for both growth and valuation comfort. The company is listed and trades on the National Stock Exchange of India, and its trading status is shown as Active.

Listing profile and industry classification

The company’s status is shown as Listed, with a date of listing: 19-Dec-2024. In industry classification, it is placed under Software & IT Services (sector) and Software (industry). A separate classification block also tags the basic industry as IT Enabled Services, consistent with its healthcare workflow and operations platform positioning.

IKS is headquartered in Thane, Maharashtra, and the company is based in Navi Mumbai, India.

Business model: technology-enabled healthcare solutions

Inventurus Knowledge Solutions Limited operates as a technology-enabled healthcare solutions provider. It offers a care enablement platform that helps physician enterprises manage outpatient and inpatient care activities. The company’s platform is described as serving healthcare organizations such as health systems and integrated delivery networks, academic medical centers, multi-specialty and single-specialty medical groups, and other outpatient healthcare delivery organizations.

Geographically, the platform is stated to support provider businesses in the United States, Canada, and Australia. A separate company description also positions IKS Health as a platform that helps provider enterprises achieve clinical, financial, and operational excellence at scale, taking on administrative and clinical burdens so clinicians can focus on care.

Scale, workforce, and leadership details

The provided profile states the company was founded in 2006 and has a workforce of over 6,500 members, including over 1,300 physicians and over 300 technology experts. Leadership details in the text include CEO: Sachin K. Gupta and a founder reference to Joe Benardello (in an IKS Health profile block).

The chairman is listed as Berjis Minoo Desai. The managing director field appears blank in the provided data.

Key financial and market metrics reported

The dataset provides a compact set of market and financial indicators commonly used by equity investors to compare peers in IT-enabled and platform-led services.

• Market capitalisation: ₹27,376 Cr
• Revenue (TTM): ₹1,818 Cr
• Net Profit (TTM): ₹370 Cr
• ROE: 37.6%
• ROCE: 31.8%
• P/E: 56.3
• P/B: 15.3
• EV/EBITDA: 34.5
• Dividend yield: 0%
• Book value: ₹67.7
• EPS: ₹21.9
• Shares outstanding: 171,573,159

Another financial block in the same text also lists:

• CFO: ₹1,326.18 Cr
• EBITDA: ₹1,863.66 Cr
• Net Profit: ₹1,396.33 Cr

Because these figures appear in separate blocks, readers should treat them as reported data points from the source text rather than a single reconciled financial statement.

Valuation context versus peers (as reported)

A valuation comparison in the provided information states that, as of 25-Jul-2025, the stock traded at a premium to peers on commonly tracked multiples.

The text reports:

• P/B of 15.30x, described as a 165% premium to the peers’ median 5.77x.
• P/E of 56.32x, described as a 49% premium to the peers’ median 37.71x.

This framing matters for investors because it sets expectations: higher multiples typically require sustained execution and visibility on earnings and cash generation, while still exposing the stock to compression if market risk appetite changes.

Promoter holdings and pledging

The prominent promoters and their holdings are listed as:

• Aryaman Jhunjhunwala DiscretionaryTrust: 16.37%
• Aryavir Jhunjhunwala DiscretionaryTrust: 16.37%
• Nistha Jhunjhunwala DiscretionaryTrust: 16.37%
• Sachin Gupta: 10.23%

The text also states there is no promoter pledging in Inventurus Knowledge Solutions Ltd.

Asset base and historical price reference

The total asset value is reported at ₹2,880 Cr as on 31-Mar-24. A separate historical price snapshot states the share price was ₹1,598.00 (NSE) and ₹1,595.60 (BSE) as of 25-Jul-2025 IST.

These reference points help investors connect balance-sheet scale with market value and observe how price levels have shifted across time windows provided in the dataset.

Summary table of key reported data

Investor contacts and registered intermediary details

The investor contact details listed include Sameer Chavan, Company Secretary and Compliance Officer, with address at 801, Building No.5&6, 8th Floor, Mindspace Business Park (SEZ), Thane-Belapur Road, Airoli, Navi Mumbai – 400708, Thane, Maharashtra, India. The telephone is listed as +91-22-3964-3205, email as company.secretary@ikshealth.com, and website as www.ikshealth.com. The company identifiers shown include CIN: L72200MH2006PLC337651 and GST No: 27AABCI5573J1ZA.

The text also lists Saransh Mundra under Investor Relations and mentions a contact person, Shanti Gopalkrishnan, with SEBI Registration No.: INR000004058.

What investors typically watch from here

Based on the reported dataset, investors are likely to track three factual anchors: the stock’s movement around the ₹1,700 level, the gap between the reported valuation multiples and peers’ medians, and the consistency of reported profitability and cash-flow metrics across disclosures. With the company positioned as a healthcare provider enablement platform serving the US, Canada, and Australia, investors also tend to follow how scale and operational delivery translate into reported revenue and profit metrics over time.

For now, the next concrete datapoints would typically come from the company’s subsequent exchange filings and periodic financial updates, which would clarify how the various reported TTM and profitability figures align in the latest reporting period.